PIAZZA, FRANCESCO
 Distribuzione geografica
Continente #
NA - Nord America 8829
EU - Europa 1299
AS - Asia 517
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 4
SA - Sud America 1
Totale 10655
Nazione #
US - Stati Uniti d'America 8816
IT - Italia 471
CN - Cina 442
DE - Germania 242
FI - Finlandia 161
SE - Svezia 150
UA - Ucraina 110
GB - Regno Unito 69
VN - Vietnam 41
FR - Francia 27
RU - Federazione Russa 27
IE - Irlanda 19
IN - India 16
CA - Canada 11
JP - Giappone 10
ES - Italia 9
NL - Olanda 6
EU - Europa 5
AU - Australia 4
DK - Danimarca 2
MX - Messico 2
SA - Arabia Saudita 2
TW - Taiwan 2
CH - Svizzera 1
CL - Cile 1
CZ - Repubblica Ceca 1
GR - Grecia 1
HU - Ungheria 1
IL - Israele 1
IQ - Iraq 1
KW - Kuwait 1
MK - Macedonia 1
PL - Polonia 1
TR - Turchia 1
Totale 10655
Città #
Fairfield 1546
Woodbridge 1012
Ann Arbor 953
Chandler 856
Houston 762
Ashburn 612
Cambridge 575
Seattle 558
Wilmington 499
Jacksonville 489
Princeton 196
San Diego 174
Padova 148
Medford 127
Beijing 111
Nanjing 94
Des Moines 92
Boardman 62
Helsinki 59
Dong Ket 41
Roxbury 34
Shenyang 30
Jinan 28
Hebei 25
Guangzhou 24
Nanchang 23
Changsha 19
Redwood City 17
Milan 15
Tianjin 15
Dublin 13
Jiaxing 12
Malo 12
Norwalk 12
Kharkiv 10
Falls Church 9
Phoenix 8
Borås 7
Hefei 7
London 7
Taizhou 7
Verona 7
Bologna 6
Nürnberg 6
Shibuya 6
Taiyuan 6
Venezia 6
Indiana 5
Madrid 5
Mountain View 5
Ningbo 5
Rockville 5
Vittorio Veneto 5
Bolzano 4
Kunming 4
North York 4
Pignone 4
Bassano del Grappa 3
Cervignano del Friuli 3
Chicago 3
Florence 3
Hangzhou 3
Hanover 3
Ladispoli 3
Lonigo 3
Paris 3
Regensburg 3
Selvazzano Dentro 3
Tokyo 3
Venice 3
Vicenza 3
Zhengzhou 3
Caldogno 2
Fuzhou 2
Haikou 2
Istrana 2
Las Vegas 2
Livorno 2
Marcon 2
Marostica 2
Melbourne 2
Montréal 2
New York 2
Nuremberg 2
Palermo 2
Piazzola Sul Brenta 2
Ro 2
Rome 2
San Giovanni Valdarno 2
Sant'elena 2
Shanghai 2
Silea 2
Taipei 2
Treviolo 2
Wuhan 2
Abano Terme 1
Adria 1
Alcamo 1
Alghero 1
Amsterdam 1
Totale 9479
Nome #
R-Vemp Is a Safe and Effective Chemo-Immunotherapeutic Regimen In Elderly Unfit DLBCL Patients: Report From a Single Center-Experience 304
Prosurvival autophagy is regulated by protein kinase CK1 alpha in multiple myeloma 146
HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia 145
Dominant cytotoxic NK cell subset within CLPD-NK patients identifies a more aggressive NK cell proliferation 140
Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients 133
The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma 131
Protein kinase CK2 regulates AKT, NF-κB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia 129
3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763), a Glycogen Synthase Kinase-3 Inhibitor, Displays Therapeutic Properties in a Mouse Model of Pulmonary Inflammation and Fibrosis 126
Peripheral neuropathies in chronic lymphocytic leukemia: a single center experience on 816 patients. 120
STAT3 mutation impacts biological and clinical features of T-LGL leukemia 118
Possible neuroleukemiosis in two patients with acute myeloid leukemia in complete bone marrow remission 118
Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia 117
Aberrant expression of CD10 and BCL6 in mantle cell lymphoma 117
Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia 114
Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity 113
Double autologous bone marrow transplantation and orthotopic liver transplantation in a patient with primary light chain (AL) amyloidosis. 113
Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic Leukemia 112
Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival 111
Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells. 111
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death 109
Towards a new age in the treatment of multiple myeloma 108
Serine-Threonine protein kinases CK1, CK2 and GSK3 in normal and malignant haematopoiesis 106
Protein Kinase CK2 Inhibition Down Modulates the NF-κB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells 105
Targeting CK2-driven non-oncogene addiction in B-cell tumors 105
Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: A report of three cases 105
Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation 104
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas 104
In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment 100
Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments 99
Severe infections unrelated to neutropenia impact on overall survival in multiple myeloma patients: results of a single centre cohort study 98
Modeling acute promyelocytic leukemia in the mouse: new insights in the pathogenesis of human leukemias. 97
Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia 97
BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome 96
Comparative Analysis of NK Receptor and T-Cell Receptor Repertoires in Patients with Chronic Myeloid Leukemia Treated with Different Tyrosine Kinase Inhibitors 95
Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity 95
Modulation of ER Stress/Unfolded Protein Response (UPR) Pathways in Multiple Myeloma Cells by Inhibition of Hsp90 and Serine-Threonine Kinase CK2. 95
Double autologous bone marrow transplantation and orthotopic liver transplantation in a patient with primary light chain (AL) amyloidosis 93
Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death 93
Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine 92
Detection of monoclonal T populations in patients with KIR-restricted chronic lymphoproliferative disorder of NK cells. 90
CX-4945, a selective inhibitor of casein kinase 2, synergizes with B cell receptor signaling inhibitors in inducing diffuse large B cell lymphoma cell death 90
Inhibition of leukocyte elastase, polymorphonuclear chemoinvasion, and inflammation-triggered pulmonary fibrosis by a 4-alkyliden-beta-lactam with a galloyl moiety 89
Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2 86
Dabigatran in ibrutinib-treated patients with atrial fibrillation and lymphoproliferative diseases: Experience of 4 cases 86
Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia 86
Role of protein kinase CK2 in the retinoic acid-induced differentiation of acute promyelocytic leukemia cells. 85
Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth. 85
Role of GSK3 in multiple myeloma cell growth and survival 83
Effects of CK2 inhibition on multiple signaling pathways in myeloma cells. 82
Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and ß-catenin survival signaling pathways 82
Old and young actors playing novel roles in the drama of multiple myeloma bone marrow microenvironment dependent drug resistance 81
Signalling molecules as selective targets for therapeutic strategies in multiple myeloma 81
Actionable Strategies to Target Multiple Myeloma Plasma Cell Resistance/Resilience to Stress: Insights From “Omics” Research 79
Genotypic evaluation of killer immunoglobulin-like receptors in NK-type lymphoproliferative disease of granular lymphocytes 78
Regulation of alveolar macrophage-T cell interactions during Th1-type sarcoid inflammatory process 78
Modulation of ER Stress/Unfolded Protein Response (UPR) Pathways in Multiple Myeloma Cells by Inhibition of Hsp90 and Serine-Threonine Kinase CK2. 78
Analysis of Wnt and Hedgehog Pathways Regulating Protein Kinases CK1 and CK2 in Acute Myeloid Leukemia Cells and Stem Cells: Correlation with the Expression of Wnt and Hedgehog Targets and Biological and Clinical Features 78
Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. 77
Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response 76
Molecular therapeutic approaches to acute myeloid leukemia: targeting aberrant chromatin dynamics and signal transduction 75
Protein kinase CK2 in normal and malignant hematopoiesis 75
Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy 75
A SCORING SYSTEM TO PREDICT THE RISK OF ATRIAL FIBRILLATION IN CHRONIC LYMPHOCYTIC LEUKEMIA 74
B7 costimulatory molecules from malignant cells in patients with B-cell chronic lymphoproliferative disorders trigger T-cell proliferation 73
Peripheral nervous system involvement in lymphomas 73
Hyperforin blocks neutrophil activation of MMP-9, motility and recruitment, and restrains inflammation-triggered angiogenesis and lung fibrosis 72
Analysis of TNF-receptor and ligand superfamily molecules in patients with lymphoproliferative disease of granular lymphocytes 72
Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma 72
Hyperforin blocks neutrophil activation of matrix metalloproteinase-9, motility and recruitment, and restrains inflammation-triggered angiogenesis and lung fibrosis 69
Multiple myeloma cells survival and proliferation rely on high levels and activity of the serine-threonine kinase CK2. 69
Ibrutinib in relapsed hairy cell leukemia variant: a case report and review of the literature 69
Cytokines, chemokines and other biomolecular markers in sarcoidosis 68
Inhibition of protein kinase CK2 affects the homeostasis of the unfolded protein response pathways in multiple myeloma cells and empowers the cytotoxic effect of Hsp90 inhibitors 68
Expression and functional role of chemokine receptors in multiple myeloma 68
Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies 68
CK2 Kinase Inhibitors Display Anti-Myeloma Effects and Antagonize Osteoclast Activity in Models of Multiple Myeloma Bone Marrow Microenvironment 67
Multiple myeloma cell survival relies on high activity of protein kinase CK2 67
Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity 67
Expression and functional role of CXCR3 on malignant B cells from patients with B-cell chronic disorders 65
Expression and functional role of chemokine receptors in multiple myeloma 65
Identification of the true hyperdiploid multiple myeloma subset by combining conventional karyotyping and FISH analysis 65
New responsibilities for aged kinases in B-lymphomas 65
Multiple myeloma cells survival and proliferation rely on high levels and activity of the serine-threonine kinase CK2. 65
NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias 63
Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations 62
Novel players in multiple myeloma pathogenesis: role of protein kinases CK2 and GSK3. 62
PLZF controls the homeostasis of the hemopoietic stem cell compartment. 61
Pokemon is required for terminal differentiation in multiple tissues. 58
The chemokine receptor CXCR3 is expressed on malgnat B cells and mediates chemotaxis. 57
Characterization of PLZP, a novel PLZF-related factor. 56
Pokemon is essential for terminal myeloid and erythroid differentiation. 56
Targeted disruption of the PLZF APL-associated gene homologue, PLZP, in the mouse. 56
Rituximab, Bendamustine and Cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma 56
Serum vascular endothelial growth factor (VEGF) in the differential diagnosis of amyloid neuropathy and POEMS syndrome. 55
Disruption of PLZP in mice leads to increased T-lymphocytes proliferation, cytokine production and altered hematopoietic stem cell homeostasis 55
Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection 55
The theory of APL. 54
Lymph node core needle biopsy in lymphoproliferative disorders - Authors' reply to Al-Abbadi and colleagues 53
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties 52
GSK3 blockade prevents bleomycin-induced lung inflammation and fibrosis. 51
Totale 8792
Categoria #
all - tutte 19030
article - articoli 15812
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 382
Totale 35224


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/2018156 0000 00 012 829242
2018/2019990 5421188 1013 1178 23145281247
2019/20202313 2807724170 203178 203266 230300222160
2020/20212332 168168160221 4093 170185 292419256160
2021/20222172 131244224104 131142 100242 12649248431
2022/20231385 34717245258 280210 2845 0000
Totale 10860